It was good news for Novartis and bad news for Merck KGaA this week as regulators handed down their decisions on each company’s multiple sclerosis (MS) drug candidate.
Browsing: 4807
Patients hoping for a new alternative to the blockbuster blood thinner Plavix will have to wait a bit longer for a verdict on a promising candidate.
Onyx Pharmaceuticals has agreed to purchase private biotechnology company Proteolix for $276 million in cash.